Lymphoproliferative lesions that have morphology between benign and malignant are difficult to diagnose even with immunohistochemical and clonality testing. The correct diagnosis is necessary for the prompt treatment. These lesions can also serve as instructive models of lymphomagenesis. FOXP1 plays an important role in B-cell development, has a potential oncogene in B-cell Non-Hodgkin lymphoma, and p53 protein has a crucial role in the regulation of cell cycle, DNA repair, apoptosis, and senescence tumor suppression activity. In this study, we analyze the role of FOXP1 and p53 expression in reactive lymphoid hyperplasia and B-cell Non-Hodgkin lymphoma, large cell type. 68 paraffin blocks samples from patients diagnosed as reactive lymphoid hyperplasia and B-cell Non-Hodgkin lymphoma, large cell type was sectioned and stained with immunohistochemistry for FOXP1 and p53, and the percentage of nuclear cells showing positive staining were evaluated. Expression of FOXP1 and p53 in B-cell Non-Hodgkin lymphoma, large cell type is higher than in reactive lymphoid hyperplasia with p=0.001 and cutoff point 45%(CI=95%) for FOXP1 and p=0.001 and cutoff point 7.5%(CI=95%) for p53. There is a significant correlation between the expression of FOXP1 and p53 in reactive lymphoid hyperplasia and B-cell Non-Hodgkin lymphoma, large cell type (p=0.001). Our findings suggest that high expression of FOXP1 and p53 in B-cell Non-Hodgkin lymphoma may demonstrate the role of FOXP1 and p53 in lymphomagenesis and these markers may help to distinguish benign and malignant lymphoproliferative lesions.
|Number of pages||7|
|Journal||Indian Journal of Forensic Medicine and Toxicology|
|Publication status||Published - 1 Jan 2021|
- B-cell Non-Hodgkin lymphoma
- Reactive lymphoid hyperplasia